• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

#ES­MO17 roundup: Idera shares spike on ear­ly TLR9 com­bo da­ta; Ery­tech touts pan­cre­at­ic can­cer PhI­Ib da­ta

8 years ago
R&D

Trou­bled Te­va poach­es Lund­beck CEO Schultz with an of­fer he could­n't refuse, in­clud­ing $20M in cash

8 years ago
People

#ES­MO17: Roche ex­tends los­ing streak with a set­back for Zelb­o­raf as No­var­tis com­bo surges ahead

8 years ago
R&D

J&J scraps a multi­bil­lion-dol­lar he­pati­tis C pro­gram af­ter ri­vals divvy up the mar­ket

8 years ago
R&D

#ES­MO17: Bris­tol-My­ers posts da­ta on an up­set check­point com­bo vic­to­ry in front­line kid­ney can­cer

8 years ago
R&D

#ES­MO17: Eli Lil­ly sets the stage for a CDK 4/6 show­down with Pfiz­er, No­var­tis — but not ex­act­ly to its ad­van­tage

8 years ago
R&D

Al­ler­gan CEO gam­bles a multi­bil­lion-dol­lar fran­chise — and his com­pa­ny rep — on a high-stakes bet at an In­di­an ...

8 years ago
Bioregnum
Opinion

#ES­MO17: As­traZeneca salves sting­ing set­back with a big win in a block­buster seg­ment of the lung can­cer mar­ket

8 years ago
R&D

Roche gets hit with an­oth­er big R&D set­back as a prospec­tive AMD block­buster flops in PhI­II

8 years ago
R&D

Pros­e­cu­tors want Shkre­li thrown in jail now af­ter Face­book threat

8 years ago
People

The top 5 trends re­shap­ing bio­phar­ma starts with an R&D earth­quake

8 years ago

Ku­ra shares soar on pos­i­tive PhII can­cer da­ta; M&A buzz re­volves back to As­traZeneca

8 years ago
News Briefing

Vas Narasimhan tapped to take No­var­tis' helm as Joe Jimenez heads to Sil­i­con Val­ley

8 years ago
Peer Review

Replimune adds a $55M round and some ex­pert help as it pur­sues next-gen on­colyt­ics R&D

8 years ago
People
Financing

#ES­MO17 ROUNDUP: Mer­ck’s da­ta on Keytru­da/chemo com­bo for lung can­cer takes ear­ly spot­light at ES­MO

8 years ago
R&D

Sanofi, Re­gen­eron earn ‘break­through’ sta­tus for a fast-track drug out to prove PD-1 dom­i­nance

8 years ago
Pharma

Fol­low­ing up on Trump's or­ders, the FDA wants to know: which reg­u­la­tions and pa­per­work re­quire­ments need to go?

8 years ago
Pharma

Ham­mered by crit­ics, NewLink strikes back with pos­i­tive PhII in­dox­i­mod da­ta — and shares rock­et up

8 years ago
R&D

Eli Lil­ly slash­es R&D jobs, shut­ters 2 re­search sites as it looks to cut 3,500 staffers world­wide

8 years ago
R&D
Pharma

Bris­tol-My­er­s' check­point com­bo scores in PhI­II study; As­traZeneca hands Cir­cas­sia pos­i­tive da­ta for COPD drug; ...

8 years ago
News Briefing

Ab­b­Vie adds more stel­lar da­ta on ABT-494 — this time for atopic der­mati­tis

8 years ago
R&D

Ramp­ing back up on on­col­o­gy, GSK takes an op­tion on Adap­ti­m­mune’s TCR can­cer drug

8 years ago
Pharma

Al­ny­lam slammed af­ter pa­tient death forces in­ves­ti­ga­tors to halt dos­ing of fi­tusir­an, rais­ing new safe­ty fears

8 years ago
Pharma

Google helps boost Grit­stone’s neoanti­gen R&D gam­ble to $195M as re­searchers prep for first hu­man study

8 years ago
Financing
Startups
First page Previous page 1088108910901091109210931094 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times